DAL BEN, Diego
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.391
EU - Europa 6.844
AS - Asia 4.636
SA - Sud America 578
Continente sconosciuto - Info sul continente non disponibili 460
AF - Africa 198
OC - Oceania 12
Totale 26.119
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.984
CN - Cina 1.864
PL - Polonia 1.721
SG - Singapore 1.371
RU - Federazione Russa 1.326
IT - Italia 1.223
DE - Germania 596
BR - Brasile 476
GB - Regno Unito 438
HK - Hong Kong 386
FR - Francia 370
VN - Vietnam 359
UA - Ucraina 337
CA - Canada 323
SE - Svezia 258
FI - Finlandia 221
KR - Corea 153
ZA - Sudafrica 139
TR - Turchia 132
IE - Irlanda 92
IN - India 89
JP - Giappone 68
NL - Olanda 58
MX - Messico 43
BD - Bangladesh 41
BE - Belgio 40
AR - Argentina 38
ES - Italia 29
EU - Europa 27
AT - Austria 22
IQ - Iraq 19
PK - Pakistan 19
EC - Ecuador 18
TW - Taiwan 16
CZ - Repubblica Ceca 15
LT - Lituania 14
AE - Emirati Arabi Uniti 13
CO - Colombia 12
IR - Iran 12
KE - Kenya 12
RO - Romania 12
RS - Serbia 12
ID - Indonesia 11
AU - Australia 10
CH - Svizzera 10
PY - Paraguay 10
TN - Tunisia 10
VE - Venezuela 10
EG - Egitto 9
JM - Giamaica 9
JO - Giordania 9
SA - Arabia Saudita 9
UZ - Uzbekistan 9
DK - Danimarca 8
IL - Israele 7
LB - Libano 7
PE - Perù 7
DZ - Algeria 6
HN - Honduras 6
PH - Filippine 6
AL - Albania 5
AM - Armenia 5
AZ - Azerbaigian 5
HU - Ungheria 5
MA - Marocco 5
MY - Malesia 5
NI - Nicaragua 5
TT - Trinidad e Tobago 5
BG - Bulgaria 4
CI - Costa d'Avorio 4
HR - Croazia 4
NP - Nepal 4
BY - Bielorussia 3
CL - Cile 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
GR - Grecia 3
LV - Lettonia 3
NO - Norvegia 3
PT - Portogallo 3
SI - Slovenia 3
TH - Thailandia 3
BB - Barbados 2
CR - Costa Rica 2
GE - Georgia 2
KH - Cambogia 2
KW - Kuwait 2
MM - Myanmar 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
OM - Oman 2
PR - Porto Rico 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
CM - Camerun 1
DM - Dominica 1
Totale 25.668
Salva come PNG Salva come JPEG
Città #
Warsaw 1.494
Fairfield 1.296
Ashburn 1.169
Woodbridge 971
Jacksonville 793
Singapore 689
Houston 629
San Jose 613
Chandler 567
Seattle 547
Wilmington 517
Council Bluffs 485
Ann Arbor 483
Cambridge 450
Dallas 382
Hong Kong 364
Boardman 355
Beijing 330
Camerino 266
Nanjing 246
Kraków 213
Los Angeles 210
Toronto 205
The Dalles 154
New York 137
Seoul 127
Johannesburg 124
Helsinki 118
San Mateo 117
Tongling 116
Dearborn 111
Lawrence 111
Princeton 111
Ho Chi Minh City 110
Columbus 109
London 107
Istanbul 104
Lauterbourg 100
Moscow 91
Dublin 90
Ogden 90
Santa Clara 84
Düsseldorf 81
Chicago 80
Shanghai 75
Buffalo 74
San Diego 74
Nanchang 71
Guangzhou 69
Milan 67
St Louis 66
Hanoi 61
São Paulo 59
Lachine 57
Tokyo 53
Munich 51
Frankfurt am Main 50
Dong Ket 49
Tianjin 49
Rome 48
Kunming 46
Edinburgh 44
Shenyang 43
Orem 41
Brussels 39
Jiaxing 38
Hebei 36
Centro 35
Phoenix 33
Denver 31
Atlanta 29
San Francisco 28
Changsha 27
Manchester 26
Montreal 26
Philadelphia 26
Hangzhou 25
Trieste 25
Jinan 23
Salt Lake City 23
Wuhan 23
Falls Church 22
Poplar 22
Redwood City 22
Amsterdam 21
Boston 21
Hefei 21
Brooklyn 20
Ningbo 20
Norwalk 20
Redondo Beach 20
Scafati 20
Chennai 19
Mexico City 19
Nuremberg 18
Stockholm 18
Bologna 17
Rio de Janeiro 17
Verona 17
Ascoli Piceno 16
Totale 17.556
Salva come PNG Salva come JPEG
Nome #
1,2,4-Triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A3 receptor antagonists. Synthesis, structure–affinity relationships and molecular modeling studies 652
A2AR agonists/A3R antagonists: design, synthesis, and biological evaluation of new ligands with dual activity 460
The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor 412
Overview on Radiolabel-Free in Vitro Assays for GPCRs 407
Pharmacological characterization of the GPR17 receptor dual profile 402
GPR17 receptor modulators and their therapeutic implications: review of recent patents 393
The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype 390
The G Protein-Coupled Receptor GPR17: Overview and Update 375
2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 368
Stabilization of the cyclodecadiene derivative isofuranodiene by silver (I) coordination. Mechanistic and biological aspects 364
2’,3’-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 360
Emerging Roles of Purinergic Signaling in Diabetes 355
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications 337
A Novel Class of Dopamine D4 Receptor Ligands Bearing an Imidazoline Nucleus 303
Adenine based acyclic-nucleotides as novel P2X3 receptor ligands 301
8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands 297
Synthesis and antitumor evaluation of bis aza-anthracene-9,10-diones and bis aza-anthrapyrazole-6-ones 294
Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia 288
P2X7 Receptor as a Therapeutic Target 285
Neuropeptide S Receptor: recent updates on non-peptide antagonist discovery 281
Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists 271
Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor 270
Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists 265
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 259
The P2X7 Receptor in Infection and Inflammation 251
Antiproliferative Evaluation of Isofuranodiene on Breast and Prostate Cancer Cell Lines 250
Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA 250
Antioxidant-conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain 247
Identification of a specific residue that confers BzATP sensitivity to P2X2 receptors 243
New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists 241
Purinergic P2X receptors: Structural models and analysis of ligand-target interaction 240
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview 240
8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A(2A) and A(2B) receptors ligands 238
Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs 237
Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17 235
“Third Joint Italian-German Purine Club Meeting - Purinergic Receptors: New Frontiers for Novel Therapies” 235
A(2A) Adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists 228
New sensible method to quantize the intestinal absorption of receptor ligands 228
Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation 226
Molecular modeling studies on the human neuropeptide S receptor and its antagonists. 224
Molecular modeling study on potent and selective adenosine A3 receptor agonists. 224
Antiviral properties of deazaadenine nucleoside derivatives 223
Evidence for the existence of a specific G protein-coupled receptor activated by guanosine 222
A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity 219
Adenosine A(2A) receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease 215
Comparison and optimization of transient transfection methods at human astrocytoma cell line 1321N1 215
Design, synthesis and evaluation in an LPS rodent model of neuroinflammation of a novel (18)F-labelled PET tracer targeting P2X7 215
Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A3 and A2A subtypes 214
Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity 214
Interaction model for anthracycline activity against DNA topoisomerase II 213
Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: Insight into the receptor activation switch 213
Adenosine receptor modeling: what does the A2A crystal structure tell us? 212
Fragment optimization for GPCRs by molecular dynamics free energy calculations: Probing druggable subpockets of the A2A adenosine receptor binding site 210
The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2B receptor 209
Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases 206
Identification of alpha(1)-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens 205
Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A1 and A2A receptor antagonists. Evaluation of their protective effect against β-amyloid-induced neurotoxicity in SH-SY5Y cells 205
The importance of alkynyl chain presence for the activity of adenine nucleosides/nucleotides on purinergic receptors 204
Pharmacological postconditioning of the rabbit heart with non-selective, A1, A2A and A3 adenosine receptor agonists 202
Innovative functional cAMP assay: application to the pharmacological characterization of GPR17 201
Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor 201
New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile 200
Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists 197
Amide bond direction modulates G-quadruplex recognition and telomerase inhibition by 2,6 and 2,7 bis-substituted anthracenedione derivatives 196
Human adenosine A3 receptor as selective target of new 2-aralkynyl-N6-methyl-MECA derivatives 195
Purinergic P2X receptors: physiological and pathological roles and potential as therapeutic targets 194
Modifications on the amino-3,5-dicyanopyridine core to obtain multifaceted adenosine receptor ligands with antineuropathic activity 194
GPCRs as therapeutic targets: a view on adenosine receptors structure and functions, and molecular modeling support 193
Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors 189
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease 189
A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable? 189
Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors Ranging from Pan Ligands to Combined A1/A2B Partial Agonists 188
Functional cAMP assay optimization at CHO cells expressing A2A adenosine receptors and stably transfected with firefly luciferase biosensor 186
Synthesis, structure-affinity relationships and molecular modeling studies of novel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists 184
Adenosine Receptors as Neuroinflammation Modulators: Role of A1 Agonists and A2A Antagonists 182
TESTING D2-LIKE RECEPTOR AFFINITY AND SELECTIVITY WITH NOVEL IMIDAZOLINE DERIVATIVES 180
Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists. Synthesis, structure-affinity relationships and molecular modeling studies 180
I protocolli operativi nella violenza di genere 180
Synthesis and stability studies of 2 ',3 ',5 '-tri-O-acetyl-2-amino(-N-6-cyclopentyl)-1-deazaadenosines 179
Adenine derivatives as inhibitors of the casein kinase CK1delta enzyme 177
Rational design of new competitive inhibitors of human CK2 activity 176
DNA Topoisomerase II Structures and Anthracycline Activity: Insights into Ternary Complex Formation 176
Purinergic P2X receptors: Structural models and analysis of receptor-ligand interaction 169
Development of novel pyridazinone-based adenosine receptor ligands 168
Highlights on the development of A(2A) adenosine receptor agonists and antagonists 167
N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A(3) adenosine receptor 159
Synthesis and biological activity of trisubstituted adenines as A(2A) adenosine receptor antagonists 157
7th Joint Italian-German Purine Club Meeting - “Advances in basic and translational purinergic research” - 20-22 luglio 2017 155
A2A adenosine receptor ligands: effects on alcohol intake in alcohol-preferring rats 155
GTP-Eu binding assay optimization for the adenosine A3 receptor ligands screening 154
The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis 154
Substituted adenine derivatives as novel P2X3 receptor ligands 152
New potent and selective A1 adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases 152
New purine derivatives as P2X3 receptor antagonists 151
Adenosine A2A Receptor Antagonists: Chemistry, SARs, and Therapeutic Potential 149
Letters in Drug Design & Discovery 148
Synthesis and biological evaluation of 2-alkynyl-N6-methyl-5'-N-methylcarboxamidoadenosine derivatives as potent and highly selective agonists for the human adenosine A(3) receptor 146
“Dual Anta-Inhibitors” of the A2A Adenosine Receptor and Casein Kinase CK1delta: Synthesis, Biological Evaluation, and Molecular Modeling Studies 145
Existence of snoRNA, microRNA, piRNA characteristics in a novel non-coding RNA: x-ncRNA and its biological implication in Homo sapiens 142
Novel potent and highly selective human A(3) adenosine receptor antagonists belonging to the 4-amido-2-arylpyrazolo[3,4-c]quinoline series: Molecular docking analysis and pharmacological studies 140
Totale 23.331
Salva come PNG Salva come JPEG
Categoria #
all - tutte 102.732
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 102.732
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.304 0 371 33 41 67 66 86 124 111 145 92 168
2022/20231.440 164 103 56 230 137 188 9 74 245 70 109 55
2023/20241.247 161 64 80 49 57 114 65 92 138 44 45 338
2024/20254.107 180 74 330 195 135 258 476 1.025 340 283 277 534
2025/20266.206 367 349 702 813 641 453 1.012 451 400 450 357 211
2026/2027740 558 182 0 0 0 0 0 0 0 0 0 0
Totale 26.119